Synthon is proud to announce the completion of two successful bioequivalence (BE) studies for Bempedoic acid, a product we are developing for our valued partners.
Scroll
Zobrazit
Swipe
Přehr
Jun 2026
Synthon announces successful bioequivalence studies for Bempedoic acid
In two pivotal BE studies for the US, bioequivalence has been shown between Synthon’s Bempedoic acid 180 mg film-coated tablets and Nexletol 180 mg tablets. The two BE studies were conducted in healthy volunteers in fasting and in fed conditions.
Our successful studies are a significant milestone in our mission to create a high-value portfolio of complex generic products and to make a meaningful difference in the lives of patients.
We are very pleased to announce that Synthon B.V. is supporting Amalia children’s fund by donating a financial gift and materials for the children in the hospital. All employees from Synthon Nijmegen contributed to the donation.
Synthon is pleased to announce that it has entered into a partnership with Saudi-based SAJA, to commercialize several products in the MENA region.
Our colleague Liselijn Wisman is raising funds during de Nijmeegse Vierdaagse for the Oogfonds. Her son Wikke has the rare Leber's disease.